SITE002-0370

completed

Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE002 (USA) (Dr. Nolan) · consented 2023-05-10

Adverse events

Serious AEs

Open data queries

Luna dropout signal

–

Adverse events

severe serious assessed 2026-08-18

Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-05-30 (study day 11); relationship: Y; serious criteria: hospitalization

moderate assessed 2026-08-18

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-06-14 (study day 26); relationship: Y

severe assessed 2026-08-18

Grade 3 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-08-05 (study day 78); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-10-25 (study day 159); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-10-26 (study day 160); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-11-21 (study day 186); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-01-29 (study day 255); relationship: N

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.